Skip to Main Content

Amid regulatory concerns over counterfeit medicines, one of the largest U.S. wholesalers failed to follow proper procedures after being notified by customers that illegitimate products had been shipped, according to a recent inspection by the Food and Drug Administration.

Specifically, McKesson (MCK) failed to identify and then quarantine “suspect or illegitimate” products. The wholesaler also did not retain samples or promptly notify other customers there was reason to believe illegitimate products were shipped. The inadequate procedures did not name specific products or types of products, but were noted in a so-called 483 report after an FDA inspection this past June and July.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.